Chemocentryx Inc (NASDAQ:CCXI) had a decrease of 17.4% in short interest. CCXI’s SI was 1.11M shares in July as released by FINRA. Its down 17.4% from 1.34M shares previously. With 407,200 avg volume, 3 days are for Chemocentryx Inc (NASDAQ:CCXI)’s short sellers to cover CCXI’s short positions. The SI to Chemocentryx Inc’s float is 4.64%. The stock increased 0.91% or $0.08 during the last trading session, reaching $8.89. About 240,793 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 11.16% since July 4, 2018 and is uptrending. It has outperformed by 6.73% the S&P500. Some Historical CCXI News: 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/03/2018 ChemoCentryx 4Q EPS 80c; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9
Lodestar Investment Counsel Llc increased Cisco Systems (CSCO) stake by 5.05% reported in 2019Q1 SEC filing. Lodestar Investment Counsel Llc acquired 10,740 shares as Cisco Systems (CSCO)’s stock rose 10.40%. The Lodestar Investment Counsel Llc holds 223,324 shares with $12.06M value, up from 212,584 last quarter. Cisco Systems now has $241.78B valuation. The stock increased 1.84% or $1.02 during the last trading session, reaching $56.48. About 12.80M shares traded. Cisco Systems, Inc. (NASDAQ:CSCO) has risen 14.75% since July 4, 2018 and is uptrending. It has outperformed by 10.32% the S&P500. Some Historical CSCO News: 23/05/2018 – 3-D Technology Announces Cisco Premier Partner Certification; 16/05/2018 – CISCO 3Q ADJ EPS 66C, EST. 65C; 15/03/2018 – DNB Nordic Technology Adds SAP, Exits IBM, Buys More Cisco; 13/04/2018 – FACTBOX-Russia’s list of U.S. imports that could be banned; 16/05/2018 – Cisco Systems 3Q Oper Cash Flow Includes $1.3 B of One-Time Foreign Taxes Related to Tax Cuts and Jobs Act; 04/04/2018 – Consumer tech gets reprieve as U.S., China spar over tariffs; 28/03/2018 – ARISTA NETWORKS SAYS ON MARCH 23, ADMINISTRATIVE LAW JUDGE AT INTERNATIONAL TRADE COMMISSION ISSUED A RECOMMENDED DETERMINATION – SEC FILING; 16/05/2018 – Cisco Sales, Profit Lifted by Corporate Spending on Networks; 06/03/2018 – Former Head of Cisco Investment International Joins Seraphim Capital, the Leading Space Tech VC; 28/03/2018 – Cisco Systems Names Maria Martinez Exec VP, Chief Customer Experience Officer
More notable recent Cisco Systems, Inc. (NASDAQ:CSCO) news were published by: Nasdaq.com which released: “Cisco Systems, Inc. (CSCO) Ex-Dividend Date Scheduled for July 03, 2019 – Nasdaq” on July 02, 2019, also Nasdaq.com with their article: “Cisco Systems (CSCO) Outpaces Stock Market Gains: What You Should Know – Nasdaq” published on July 03, 2019, Nasdaq.com published: “Dow Movers: DOW, CSCO – Nasdaq” on July 02, 2019. More interesting news about Cisco Systems, Inc. (NASDAQ:CSCO) were released by: Nasdaq.com and their article: “Cisco (CSCO) Hits 52-Week High, Can the Run Continue? – Nasdaq” published on June 12, 2019 as well as Nasdaq.com‘s news article titled: “Noteworthy ETF Inflows: QQQ, CSCO, INTC, ADBE – Nasdaq” with publication date: July 02, 2019.
Investors sentiment decreased to 0.83 in Q1 2019. Its down 0.08, from 0.91 in 2018Q4. It turned negative, as 58 investors sold CSCO shares while 739 reduced holdings. 139 funds opened positions while 519 raised stakes. 3.03 billion shares or 4.61% less from 3.17 billion shares in 2018Q4 were reported. Mcrae Capital Management accumulated 4,000 shares or 0.09% of the stock. Citadel Advisors Limited Liability Company has 53,429 shares for 0% of their portfolio. The Australia-based Amp Cap Invsts Ltd has invested 0.68% in Cisco Systems, Inc. (NASDAQ:CSCO). Godshalk Welsh Mngmt Inc accumulated 44,270 shares or 2.3% of the stock. 366,926 are held by Peapack Gladstone Financial Corp. Paradigm Asset Mgmt Ltd Liability holds 0% or 71,700 shares. Joel Isaacson And Ltd Liability Co reported 49,611 shares. Baker Avenue Asset LP invested in 0.14% or 31,242 shares. 62,512 are held by Stevens First Principles Inv. Sadoff Inv Limited Liability Company holds 5.2% in Cisco Systems, Inc. (NASDAQ:CSCO) or 1.12M shares. Brookstone Capital Management holds 10,067 shares. Rodgers Brothers accumulated 7,317 shares. Patten & Patten Inc Tn stated it has 1.75% of its portfolio in Cisco Systems, Inc. (NASDAQ:CSCO). Rench Wealth Mngmt Incorporated reported 105,835 shares or 3.74% of all its holdings. Park Circle Co invested in 55,500 shares.
Lodestar Investment Counsel Llc decreased Abbott Laboratories (NYSE:ABT) stake by 4,396 shares to 276,563 valued at $22.11 million in 2019Q1. It also reduced Intel (NASDAQ:INTC) stake by 9,849 shares and now owns 169,039 shares. Johnson & Johnson (NYSE:JNJ) was reduced too.
Since June 7, 2019, it had 1 insider purchase, and 0 sales for $557,404 activity. Shares for $557,404 were bought by BUSH WESLEY G on Friday, June 7.
Among 12 analysts covering Cisco Systems (NASDAQ:CSCO), 10 have Buy rating, 0 Sell and 2 Hold. Therefore 83% are positive. Cisco Systems had 16 analyst reports since February 12, 2019 according to SRatingsIntel. The company was downgraded on Tuesday, February 12 by Morgan Stanley. The company was maintained on Thursday, February 14 by Credit Suisse. KeyBanc Capital Markets maintained the stock with “Overweight” rating in Thursday, February 14 report. Cowen & Co maintained Cisco Systems, Inc. (NASDAQ:CSCO) on Tuesday, June 25 with “Buy” rating. As per Thursday, February 14, the company rating was maintained by Wells Fargo. On Monday, March 25 the stock rating was maintained by KeyBanc Capital Markets with “Overweight”. As per Thursday, February 14, the company rating was maintained by Bank of America. The rating was maintained by Goldman Sachs on Tuesday, April 16 with “Buy”. Citigroup maintained Cisco Systems, Inc. (NASDAQ:CSCO) rating on Thursday, February 14. Citigroup has “Buy” rating and $56 target. Raymond James maintained the stock with “Buy” rating in Thursday, June 20 report.
Investors sentiment increased to 1.44 in Q1 2019. Its up 0.51, from 0.93 in 2018Q4. It is positive, as 12 investors sold ChemoCentryx, Inc. shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Pnc Finance Svcs Gp accumulated 74 shares or 0% of the stock. 11,906 were reported by Element Mngmt Limited Co. 2.65 million are owned by Blackrock Inc. Product Prtnrs Ltd Liability, a New York-based fund reported 19,820 shares. Rhumbline Advisers owns 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 29,704 shares. Natl Bank Of America De stated it has 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Sei Invs holds 70,594 shares or 0% of its portfolio. Parametric Portfolio Associate Ltd Liability Com has 55,490 shares. Swiss National Bank owns 41,500 shares. Panagora Asset Management owns 308,857 shares. Franklin Resources accumulated 0.01% or 1.38 million shares. Point72 Asset Management L P holds 400,000 shares or 0.03% of its portfolio. Fernwood Investment Management Lc holds 10,000 shares. Sio Lc invested in 1.99% or 530,175 shares. Vanguard Gru reported 1.29M shares.
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Seekingalpha.com which released: “InflaRx downdraft engulfs ChemoCentryx, down 28% premarket – Seeking Alpha” on June 05, 2019, also Benzinga.com with their article: “66 Biggest Movers From Yesterday – Benzinga” published on June 06, 2019, Benzinga.com published: “10 Biggest Price Target Changes For Thursday – Benzinga” on June 06, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Seekingalpha.com and their article: “SCYNEXIS and ReWalk Robotics among healthcare gainers; Stellar Biotechnologies and ChemoCentryx among losers – Seeking Alpha” published on June 05, 2019 as well as Finance.Yahoo.com‘s news article titled: “Hedge Funds Have Never Been More Bullish On ChemoCentryx Inc (CCXI) – Yahoo Finance” with publication date: May 09, 2019.
Since January 7, 2019, it had 0 buys, and 5 insider sales for $1.38 million activity. Another trade for 6,172 shares valued at $74,079 was sold by Cappel Markus J.. Another trade for 20,170 shares valued at $242,370 was sold by Schall Thomas J.. $457,747 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) was sold by KANAYA SUSAN M on Tuesday, January 22.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $516.05 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.